TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06219122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creative arts and psychomotor therapies intervention for people with personality disorders
Description: a Group (max of 9 participants) Creative arts and psychomotor therapies (CAPTS) intervention for people with personality disorders. Consisting of 10 sessions, where two CAPTS disciplines and therapists are represented each session. Each session lasts 90 minutes. Sessions are aimed at psychological adativity thru=ough the CAPTS. The sessions cover warming up in one of the CAPTS, short psycho education and a longer assigment focusing on the session goal. The first half of the interventions focusses mainly on listening to body signals, emotions and emotional needs and dealing in a healthy way with these. The second half will be more complex when dealing with challenges and adapting tot he context in a healthy way are goals of the sessions.
Study: NCT06222736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocabado Exercises
Description: Patients trained by Rocabado Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocabado Exercises
Description: Patients trained by Rocabado Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Servical Core Exercises
Description: Servical Core Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Servical Core Exercises
Description: Servical Core Exercises
Study: NCT04700072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsule at a specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsule at a specified dose on specified days
Study: NCT05018091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: 4mg intravenous dexamethasone, administered shortly after induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 8 Mg/mL Injectable Suspension
Description: 8mg intravenous dexamethasone, administered shortly after induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 16mg
Description: 16mg intravenous dexamethasone, administered shortly after induction of anesthesia
Study: NCT05032911

Intervention type: DIAGNOSTIC_TEST
Intervention: sensorimotor control analysis using inertial sensor technology
Description: Inertial Measurement Unit (IMU) sensors will measure sensorimotor control variables including active range of motion, movement speed, acceleration, smoothness of motion, head repositioning accuracy and motion coupling patterns

Intervention type: DIAGNOSTIC_TEST
Intervention: sensorimotor control analysis using inertial sensor technology
Description: Inertial Measurement Unit (IMU) sensors will measure sensorimotor control variables including active range of motion, movement speed, acceleration, smoothness of motion, head repositioning accuracy and motion coupling patterns
Study: NCT05177328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. hominis A 9 Product
Description: Commensal staph species, phosphate buffered saline, and glycerol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline and glycerol
Study: NCT06596356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] TS-172
Description: Subjects will receive single dose of about 30 mg of TS-172 containing 1 MBq \[14C\]TS-172 as an oral solution
Study: NCT06538064

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06671548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: * Relugolix (40 mg) tablet administered orally once daily；~* megestrol acetate (1 mg) administered orally once daily；~* medroxyprogesterone acetate (2 mg) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Relugolix placebo
Description: Relugolix (0 mg) tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~megestrol acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~medroxyprogesterone acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
Study: NCT06617364

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrointestinal transit time measurement using MSOT and ICG contrast agent
Description: The subject arrives at the clinic in the morning, fasting according to the preparation instructions from the Childrens Hospital Erlangen for the H2 breath test. Before taking the liquid containing lactose and ICG, the first measurement is performed using MSOT, followed by the H2 breath test. After the liquid to be detected is fully consumed, the second H2 breath test measurement, which only takes a few minutes, is conducted. According to the official guidelines of the Childrens Hospital Erlangen, the hydrogen concentration in the breath is measured at 30-minute intervals. During the 30-minute breaks, further MSOT measurements are carried out, also at 30-minute intervals. Each of these only takes about 10 minutes, they do not interfere with the H2 breath test measurement routine. After the ninth and final H2 breath test measurement a final MSOT examination is conducted. Afterwards participants are offered an optional MRI examination, which can be used to measure intestinal motility.
Study: NCT06617806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up by the Advanced Practice Nurse
Description: At each follow-up (FU), the recommendations of an APN may include :~* Referral to a specialized memory assessment in case of cognitive impairment~* Psychological FU in the event that APN detects any mood complaints~* Ophthalmological and/or ear, nose, and throat consultation if any auditory or visual difficulties is observed~* Compression stockings use if orthostatic hypotension is present~* Nutritional counseling, with particular emphasis on the intake of protein, in combination with long-term assessment of weight~* Supplementation with vitamin D and calcium based to prevent osteoporosis in older adults, especially those at risk of recurrent falls~* Proposal of a standardized and personalized physical activity program~* Evaluation of medication therapies, especially antipsychotics, blood pressure medication or broad anticholinergics. The STOPPFall tool will be also proposed and coordinated by APN in accordance with the patient's physician~* A comprehensive social evaluative approach
Study: NCT06065774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft
Description: Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft
Description: Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene.
Study: NCT05117034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nacl 0.9%
Description: Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
Study: NCT05314283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DV3395 C1
Description: Participants will be exposed to and swallow DV3395 C1 once. The participants will stay at the clinic research center for up to 6 days .
Study: NCT05590871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlashPoint renal denervation system
Description: Radio-frequency ablation of renal arterial sympathetic nerves

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
Study: NCT06674408

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Control group included Hot pack over shoulder region for 15 mins. Shoulder AP, PA and inferior glides (Maitland) Grade II, III, IV 30 reps x 3 sets per session, Stretching of levator scapula, upper trapezius, pectoralis major and minor with 15 second hold x 3 reps per session, Strengthening of rotator cuff muscles by manual resistance with 10 second hold x 5 reps x 2 sets per muscle per session, Finger Ladder Exercise, Codman's Pendulum Exercise, Towel Stretch Exercise and Wand Exercises 10 reps x 2 sets per session,~Patients were assessed for baseline measurements against outcome measures. Patients were given a total of 10 sessions such that 5 sessions per week for the duration of 02 weeks. All patients were reassessed at the end of the 1st and 2nd week of treatment for outcome measures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prioprioceptive group
Description: Experimental group included Hot pack over shoulder region for 15 mins. Shoulder AP, PA and inferior glides (Maitland) Grade II, III, IV 30 reps x 3 sets per session, Stretching of levator scapula, upper trapezius, pectoralis major and minor with 15 second hold x 3 reps per session, Strengthening of rotator cuff muscles by manual resistance with 10 second hold x 5 reps x 2 sets per muscle per session, Plyometric CKC shoulder exercise 10 seconds each x 5 reps x 2 sets per session, CKC exercise on the ball 10 seconds each x 5 reps x 2 sets per session, Open KC exercises 10 seconds each x 5 reps x 2 sets per session, Hand-eye coordination exercises for 30 minutes/per day for 5x/per week, Hand Function Exercises for 30 minutes/per day for 5x/per week.~Patients were assessed for baseline measurements against outcome measures. Patients were given a total of 10 sessions such that 5 sessions per week for the duration of 02 weeks. All patients were reassessed at the end of the 1st and 2nd week
Study: NCT06673771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabiliation Therapy
Description: Moving the eye horizontally between two stationary target while keeping the head still Moving the eye vertically between two stationary target while keeping the head still Moving the target horizontally and tracking it with the eye while keeping the head still Moving the target vertically and tracking it with the eye while keeping the head still Moving the head horizontally while a keeping a look on stationary target Moving the head vertically while a keeping a look on stationary target Moving the head and target in opposite direction horizontally while tracking the target with eyes Moving the head and target in opposite direction vertically while tracking the target with eyes.~Sit down and stand up, sit down and stand up with eye open and eye close Stand up, but turn to the right while standing Stand up, but turn to the left while standing Place an object on the floor. Take it and bring it above your head and place it on the floor again

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Standing balance training, weight shifting training, walking training, muscle strength training, step-up-and-down training.
Study: NCT04837547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
Description: There will be two immunotherapy products manufactured and administered to subjects enrolled on this trial. The first product will be autologous dendritic cells (DCs) loaded with total tumor messenger ribonucleic acid (mRNA) (TTRNA) derived from malignant tumors. The second product will be autologous T lymphocytes stimulated ex vivo against TTRNA antigens for autologous transfer (TTRNA-xALT). DCs are professional antigen-presenting cells critical for the initiation of B and T-cell responses in vivo.
Study: NCT04544007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
Study: NCT05830695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human treated dentin matrix
Description: human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: mineral trioxide aggregate was used as control
Study: NCT06427538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Flush
Description: sterile saline 20 mL flushed into their catheter by trained nurses or study team members every 6 ± 2 hours
Study: NCT05262400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 + PF-07104091 combination dose escalation
Description: PF-07104091 and PF-07220060 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 + PF-07104091 combination dose escalation
Description: PF-07104091 and PF-07220060 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 + PF-07104091 combination dose escalation
Description: PF-07104091 and PF-07220060 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 + PF-07104091 combination dose escalation
Description: PF-07104091 and PF-07220060 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 + PF-07104091 combination dose escalation
Description: PF-07104091 and PF-07220060 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 + PF-07220060 + fulvestrant dose expansion
Description: PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 + PF-07220060 + fulvestrant dose expansion
Description: PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 + PF-07220060 + letrozole dose expansion
Description: PF-07104091 and PF-07220060 will be administered orally in combination with letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 + PF-07104091 combination dose escalation
Description: PF-07104091 and PF-07220060 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 + PF-07104091 combination dose escalation
Description: PF-07104091 and PF-07220060 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 + PF-07104091 combination dose escalation
Description: PF-07104091 and PF-07220060 will be administered orally
Study: NCT06150898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prospective data and sample collection
Description: Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prospective data and sample collection
Description: Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prospective data and sample collection
Description: Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prospective data and sample collection
Description: Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 Mg Oral Tablet
Description: Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 Mg Oral Tablet
Description: Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
Study: NCT05865886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: BI 1291583

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 1291583
Study: NCT06541301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICC-port
Description: Implantation of a PICC-port device by a dedicated PICC team member following predefined evidence-based international guidelines and protocols
Study: NCT06026787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10 mg will be added to the standard of care regimen of primary nephrotic syndrome patients
Study: NCT06541301

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest-port
Description: Implantation of a Chest-port device by expert physicians or certified expert nurses, following predefined evidence-based international guidelines and protocols
Study: NCT06678503

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance exercise
Description: Balance exercises are physical activities designed to improve stability, coordination, and posture by challenging the body's ability to maintain an upright position. These exercises target the muscles and systems involved in balance, particularly the core, legs, and the sensory systems (like vision and proprioception).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance exercise
Description: Balance exercises are physical activities designed to improve stability, coordination, and posture by challenging the body's ability to maintain an upright position. These exercises target the muscles and systems involved in balance, particularly the core, legs, and the sensory systems (like vision and proprioception).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercises
Description: Core stability exercises are physical activities designed to improve the strength, endurance, and coordination of the muscles that support and stabilize the spine, pelvis, and torso. These exercises specifically target the muscles of the abdomen, lower back, hips, and pelvis, collectively referred to as the core. The goal is to enhance overall posture, prevent injury, and improve performance in daily activities or sports by increasing the body's ability to stabilize itself during movement.
Study: NCT06594627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart pillow
Description: Utilize a smart pillow that is designed to reduce snoring issues and OSA symptoms during sleep
Study: NCT04784299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE volume plus
Description: Hyaluronic acid dermal filler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Lyft with Lidocaine
Description: Hyaluronic acid dermal filler
Study: NCT06594068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE (Furie 2017). Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo (Furie 2019; Morand 2020). Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo (Furie 2017). These data resulted with applications to the FDA and the EMA, leading to approval by them in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.